Core myopathies and malignant hyperthermia susceptibility: A review

Paediatric Anaesthesia

Volumn 23, Issue 9, 2013, Pages 834-841

  Brislin, Robert P ^a,b   Theroux, Mary C ^a,b  

^a NEMOURS ALFRED I DUPONT HOSPITAL FOR CHILDREN   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

anesthesia; congenital myopathy; core myopathy; genetics; malignant hyperthermia; ryanodine receptor

Indexed keywords

ALPHA TROPOMYOSIN; LAMIN A; LAMIN C; MYOSIN HEAVY CHAIN BETA; NEBULIN; RYANODINE RECEPTOR; SELENOPROTEIN;

ARTHROGRYPOSIS; CENTRAL CORE DISEASE; CENTRONUCLEAR MYOPATHY; DISEASE PREDISPOSITION; HUMAN; MALIGNANT HYPERTHERMIA; MISSENSE MUTATION; MULTIMINICORE DISEASE; MUSCLE BIOPSY; MUSCLE WEAKNESS; MYOPATHY; NEMALINE MYOPATHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; REVIEW;

ANESTHESIA; CONGENITAL MYOPATHY; CORE MYOPATHY; GENETICS; MALIGNANT HYPERTHERMIA; RYANODINE RECEPTOR;

ANESTHESIA; ANESTHETICS; CHILD; DISEASE SUSCEPTIBILITY; HUMANS; MALIGNANT HYPERTHERMIA; MYOPATHY, CENTRAL CORE; PATIENT CARE PLANNING; RYANODINE RECEPTOR CALCIUM RELEASE CHANNEL;

EID: 84881559289     PISSN: 11555645     EISSN: 14609592     Source Type: Journal    
DOI: 10.1111/pan.12175     Document Type: Review

References (75)

1. Amburgey K, McNamara N, Bennett LR, et al,. Prevalence of congenital myopathies in a representative pediatric united states population. Ann Neurol 2011; 70: 662-665.
2. Nance JR, Dowling JJ, Gibbs EM, et al,. Congenital myopathies: an update. Curr Neurol Neurosci Rep 2012; 12: 165-174.
3. Jungbluth H, Sewry CA, Muntoni F,. Core myopathies. Semin Pediatr Neurol 2011; 18: 239-249.
4. Jungbluth H, Wallgren-Pettersson C, Laporte J,. Centronuclear (myotubular) myopathy. Orphanet J Rare Dis 2008; 3: 26.
5. Klein A, Jungbluth H, Clement E, et al,. Muscle magnetic resonance imaging in congenital myopathies due to ryanodine receptor type 1 gene mutations. Arch Neurol 2011; 68: 1171-1179.
6. Wattjes MP, Kley RA, Fischer D,. Neuromuscular imaging in inherited muscle diseases. Eur Radiol 2010; 20: 2447-2460.
7. Jungbluth H,. Multi-minicore disease. Orphanet J Rare Dis 2007; 2: 31.
8. Wu S, Ibarra MC, Malicdan MC, et al,. Central core disease is due to RYR1 mutations in more than 90% of patients. Brain 2006; 129 (Pt 6): 1470-1480.
9. Sei Y, Sambuughin NN, Davis EJ, et al,. Malignant hyperthermia in North America: genetic screening of the three hot spots in the type I ryanodine receptor gene. Anesthesiology 2004; 101: 824-830.
10. Dubowitz V, Roy S,. Central core disease of muscle: clinical, histochemical and electron microscopic studies of an affected mother and child. Brain 1970; 93: 133-146.
11. Magee KR, Shy GM,. A new congenital non-progressive myopathy. Brain 1956; 79: 610-621.
12. Jungbluth H, Lillis S, Zhou H, et al,. Late-onset axial myopathy with cores due to a novel heterozygous dominant mutation in the skeletal muscle ryanodine receptor (RYR1) gene. Neuromuscul Disord 2009; 19: 344-347.
13. De Cauwer H, Heytens L, Lübke U, et al,. Discordant light microscopic, electron microscopic, and in vitro contracture study findings in a family with central core disease. Clin Neuropathol 1997; 16: 237-242.
14. Mercuri E, Cini C, Counsell S, et al,. Muscle MRI findings in a three-generation family affected by Bethlem myopathy. Eur J Paediatr Neurol 2002; 6: 309-314.
15. Jungbluth H, Dowling JJ, Ferreiro A, et al,. 182nd ENMC International Workshop: RYR1-related myopathies, 15-17th April 2011, Naarden, The Netherlands. Neuromuscul Disord 2012; 22: 453-462.
16. Jungbluth H, Müller CR, Halliger-Keller B, et al,. Autosomal recessive inheritance of RYR1 mutations in a congenital myopathy with cores. Neurology 2002; 59: 284-287.
17. McCarthy TV, Quane KA, Lynch PJ,. Ryanodine receptor mutations in malignant hyperthermia and central core disease. Hum Mutat 2000; 15: 410-417.
18. Treves S, Anderson AA, Ducreux S, et al,. Ryanodine receptor 1 mutations, dysregulation of calcium homeostasis and neuromuscular disorders. Neuromuscul Disord 2005; 15: 577-587.
19. Monnier N, Romero NB, Lerale J, et al,. Familial and sporadic forms of central core disease are associated with mutations in the C-terminal domain of the skeletal muscle ryanodine receptor. Hum Mol Genet 2001; 10: 2581-2592.
20. Curran JL, Hall WJ, Halsall PJ, et al,. Segregation of malignant hyperthermia, central core disease and chromosome 19 markers. Br J Anaesth 1999; 83: 217-222.
21. Engel AG, Gomez MR, Groover RV,. Multicore disease. A recently recognized congenital myopathy associated with multifocal degeneration of muscle fibers. Mayo Clin Proc 1971; 46: 666-681.
22. Zhou H, Jungbluth H, Sewry CA, et al,. Molecular mechanisms and phenotypic variation in RYR1-related congenital myopathies. Brain 2007; 130 (Pt 8): 2024-2036.
23. Ferreiro A, Estournet B, Chateau D, et al,. Multi-minicore disease-searching for boundaries: phenotype analysis of 38 cases. Ann Neurol 2000; 48: 745-757.
24. Jungbluth H, Zhou H, Hartley L, et al,. Minicore myopathy with ophthalmoplegia caused by mutations in the ryanodine receptor type 1 gene. Neurology 2005; 65: 1930-1935.
25. Ferreiro A, Quijano-Roy S, Pichereau C, et al,. Mutations of the selenoprotein N gene, which is implicated in rigid spine muscular dystrophy, cause the classical phenotype of multiminicore disease: reassessing the nosology of early-onset myopathies. Am J Hum Genet 2002; 71: 739-749.
26. Jungbluth H, Muntoni F, Ferreiro A,; Core Myopathy Consortium. 150th ENMC International Workshop: Core Myopathies, 9-11th March 2007, Naarden, The Netherlands. Neuromuscul Disord 2008; 18: 989-996.
27. Duarte ST, Oliveira J, Santos R, et al,. Dominant and recessive RYR1 mutations in adults with core lesions and mild muscle symptoms. Muscle Nerve 2011; 44: 102-108.
28. Arbogast S, Beuvin M, Fraysse B, et al,. Oxidative stress in SEPN1-related myopathy: from pathophysiology to treatment. Ann Neurol 2009; 65: 677-686.
29. Jurynec MJ, Xia R, Mackrill JJ, et al,. Selenoprotein N is required for ryanodine receptor calcium release channel activity in human and zebrafish muscle. Proc Natl Acad Sci USA 2008; 105: 12485-12490.
30. Guis S, Figarella-Branger D, Monnier N, et al,. Multiminicore disease in a family susceptible to malignant hyperthermia: histology, in vitro contracture tests, and genetic characterization. Arch Neurol 2004; 61: 106-113.
31. Carmignac V, Salih MA, Quijano-Roy S, et al,. C-terminal titin deletions cause a novel early-onset myopathy with fatal cardiomyopathy. Ann Neurol 2007; 61: 340-351.
32. Zvaritch E, Kraeva N, Bombardier E, et al,. Ca2 + dysregulation in Ryr1(I4895T/wt) mice causes congenital myopathy with progressive formation of minicores, cores, and nemaline rods. Proc Natl Acad Sci USA 2009; 106: 21813-21818.
33. Sanoudou D, Beggs AH,. Clinical and genetic heterogeneity in nemaline myopathy-a disease of skeletal muscle thin filaments. Trends Mol Med 2001; 7: 362-368.
34. Gonatas NK,. The fine structure of the rod-like bodies in nemaline myopathy and their relation to the Z-discs. J Neuropathol Exp Neurol 1966; 25: 409-421.
35. Hernandez-Lain A, Husson I, Monnier N, et al,. De novo RYR1 heterozygous mutation (I4898T) causing lethal core-rod myopathy in twins. Eur J Med Genet 2011; 54: 29-33.
36. Agrawal PB, Greenleaf RS, Tomczak KK, et al,. Nemaline myopathy with minicores caused by mutation of the CFL2 gene encoding the skeletal muscle actin-binding protein, cofilin-2. Am J Hum Genet 2007; 80: 162-167.
37. Nance PW, Huff FJ, Martinez-Arizala A, et al,. Efficacy and safety study of arbaclofen placarbil in patients with spasticity due to spinal cord injury. Spinal Cord 2011; 49: 974-980.
38. Romero NB,. Centronuclear myopathies: a widening concept. Neuromuscul Disord 2010; 20: 223-228.
39. Nicot AS, Toussaint A, Tosch V, et al,. Mutations in amphiphysin 2 (BIN1) disrupt interaction with dynamin 2 and cause autosomal recessive centronuclear myopathy. Nat Genet 2007; 39: 1134-1139.
40. Wilmshurst JM, Lillis S, Zhou H, et al,. RYR1 mutations are a common cause of congenital myopathies with central nuclei. Ann Neurol 2010; 68: 717-726.
41. Bevilacqua JA, Monnier N, Bitoun M, et al,. Recessive RYR1 mutations cause unusual congenital myopathy with prominent nuclear internalization and large areas of myofibrillar disorganization. Neuropathol Appl Neurobiol 2011; 37: 271-284.
42. Haraki T, Yasuda T, Mukaida K, et al,. Mutatedp. 4894 RyR1 function related to malignant hyperthermia and congenital neuromuscular disease with uniform type 1 fiber (CNMDU1). Anesth Analg 2011; 113: 1461-1467.
43. Sato I, Wu S, Ibarra MC, et al,. Congenital neuromuscular disease with uniform type 1 fiber and RYR1 mutation. Neurology 2008; 70: 114-122.
44. Imagama S, Kawakami N, Tsuji T, et al,. Kyphoscoliosis associated with congenital neuromuscular disease with uniform type 1 fibers. Eur Spine J 2012; 21 (Suppl 4): S499-S504.
45. Dowling JJ, Lillis S, Amburgey K, et al,. King-Denborough syndrome with and without mutations in the skeletal muscle ryanodine receptor (RYR1) gene. Neuromuscul Disord 2011; 21: 420-427.
46. Carpenter D, Ismail A, Robinson RL, et al,. A RYR1 mutation associated with recessive congenital myopathy and dominant malignant hyperthermia in Asian families. Muscle Nerve 2009; 40: 633-639.
47. D'Arcy CE, Bjorksten A, Yiu EM, et al,. King-denborough syndrome caused by a novel mutation in the ryanodine receptor gene. Neurology 2008; 71: 776-777.
48. Reed UC, Resende MB, Ferreira LG, et al,. King-Denborough Syndrome: report of two Brazilian cases. Arq Neuropsiquiatr 2002; 60 (3-B): 739-741.
49. Lavezzi WA, Capacchione JF, Muldoon SM, et al,. Case report: death in the emergency department: an unrecognized awake malignant hyperthermia-like reaction in a six-year-old. Anesth Analg 2013; 116: 420-423.
50. Larach MG, Localio AR, Allen GC, et al,. A clinical grading scale to predict malignant hyperthermia susceptibility. Anesthesiology 1994; 80: 771-779.
51. Litman RS, Rosenberg H,. Malignant hyperthermia: update on susceptibility testing. JAMA 2005; 293: 2918-2924.
52. Larach MG, Brandom BW, Allen GC, et al,. Cardiac arrests and deaths associated with malignant hyperthermia in North America from 1987 to 2006: a report from the North American Malignant Hyperthermia Registry of the Malignant Hyperthermia Association of the United States. Anesthesiology 2008; 108: 603-611.
53. Gronert GA, Heffron JJ, Milde JH, et al,. Porcine malignant hyperthermia: role of skeletal muscle in increased oxygen consumption. Can Anaesth Soc J 1977; 24: 103-109.
54. Larach MG, Gronert GA, Allen GC, et al,. Clinical presentation, treatment, and complications of malignant hyperthermia in North America from 1987 to 2006. Anesth Analg 2010; 110: 498-507.
55. Rosero EB, Adesanya AO, Timaran CH, et al,. Trends and outcomes of malignant hyperthermia in the United States, 2000 to 2005. Anesthesiology 2009; 110: 89-94.
56. Brady JE, Sun LS, Rosenberg H, et al,. Prevalence of malignant hyperthermia due to anesthesia in New York State, 2001-2005. Anesth Analg 2009; 109: 1162-1166.
57. Robinson R, Carpenter D, Shaw MA, et al,. Mutations in RYR1 in malignant hyperthermia and central core disease. Hum Mutat 2006; 27: 977-989.
58. Maclennan DH, Zvaritch E,. Mechanistic models for muscle diseases and disorders originating in the sarcoplasmic reticulum. Biochim Biophys Acta 2011; 1813: 948-964.
59. MacLennan DH, Duff C, Zorzato F, et al,. Ryanodine receptor gene is a candidate for predisposition to malignant hyperthermia. Nature 1990; 343: 559-561.
60. McCarthy TV, Healy JM, Heffron JJ, et al,. Localization of the malignant hyperthermia susceptibility locus to human chromosome 19q12-13.2. Nature 1990; 343: 562-564.
61. Quane KA, Healy JM, Keating KE, et al,. Mutations in the ryanodine receptor gene in central core disease and malignant hyperthermia. Nat Genet 1993; 5: 51-55.
62. Mulley JC, Kozman HM, Phillips HA, et al,. Refined genetic localization for central core disease. Am J Hum Genet 1993; 52: 398-405.
63. Robinson RL, Anetseder MJ, Brancadoro V, et al,. Recent advances in the diagnosis of malignant hyperthermia susceptibility: how confident can we be of genetic testing? Eur J Hum Genet 2003; 11: 342-348.
64. Rosenberg H,. Mining for mutations in malignant hyperthermia. Anesth Analg 2011; 113: 975-976.
65. Urwyler A, Deufel T, McCarthy T, et al,. Guidelines for molecular genetic detection of susceptibility to malignant hyperthermia. Br J Anaesth 2001; 86: 283-287.
66. Pirone A, Schredelseker J, Tuluc P, et al,. Identification and functional characterization of malignant hyperthermia mutation T1354S in the outer pore of the Cavalpha1S-subunit. Am J Physiol Cell Physiol 2010; 299: C1345-C1354.
67. Stewart SL, Hogan K, Rosenberg H, et al,. Identification of the Arg1086His mutation in the alpha subunit of the voltage-dependent calcium channel (CACNA1S) in a North American family with malignant hyperthermia. Clin Genet 2001; 59: 178-184.
68. Eltit JM, Bannister RA, Moua O, et al,. Malignant hyperthermia susceptibility arising from altered resting coupling between the skeletal muscle L-type Ca2 + channel and the type 1 ryanodine receptor. Proc Natl Acad Sci USA 2012; 109: 7923-7928.
69. Carpenter D, Ringrose C, Leo V, et al,. The role of CACNA1S in predisposition to malignant hyperthermia. BMC Med Genet 2009; 10: 104.
70. Monnier N, Procaccio V, Stieglitz P, et al,. Malignant-hyperthermia susceptibility is associated with a mutation of the alpha 1-subunit of the human dihydropyridine-sensitive L-type voltage-dependent calcium-channel receptor in skeletal muscle. Am J Hum Genet 1997; 60: 1316-1325.
71. Toppin PJ, Chandy TT, Ghanekar A, et al,. A report of fulminant malignant hyperthermia in a patient with a novel mutation of the CACNA1S gene. Can J Anaesth 2010; 57: 689-693.
72. Treves S, Jungbluth H, Muntoni F, et al,. Congenital muscle disorders with cores: the ryanodine receptor calcium channel paradigm. Curr Opin Pharmacol 2008; 8: 319-326.
73. Dirksen RT, Avila G,. Altered ryanodine receptor function in central core disease: leaky or uncoupled Ca(2 +) release channels? Trends Cardiovasc Med 2002; 12: 189-197.
74. Boncompagni S, Rossi AE, Micaroni M, et al,. Characterization and temporal development of cores in a mouse model of malignant hyperthermia. Proc Natl Acad Sci USA 2009; 106: 21996-22001.
75. Chelu MG, Goonasekera SA, Durham WJ, et al,. Heat- and anesthesia-induced malignant hyperthermia in an RyR1 knock-in mouse. FASEB J 2006; 20: 329-330.